Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Open-Label Study of Maplirpacept (PF-07901801, TTI-622) Monotherapy in Japanese Participants With Relapsed or Refractory Hematologic Malignancies
jRCT2021220030Phase 1Completed
- Sponsor
- Pfizer
- Start
- Nov 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of maplirpacept in Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL) and multiple myeloma (MM), sponsored by Pfizer. Primary endpoint: Number of Participants with Dose Limiting Toxicity (DLT) in lymphoma. Started Nov 2022; status: completed.
02
Drugs
maplirpacept
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2021220030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021220030.